Literature DB >> 17650446

Demonstration of changes in plasma cell subsets in multiple myeloma.

Michael John Ayliffe1, Faith Elizabeth Davies, David de Castro, Gareth John Morgan.   

Abstract

Increases in free light chain (FLC) production are associated with disease progression in multiple myeloma (MM). Using a double immunofluorescence staining method to produce a differential count of plasma cells in bone marrow, single populations were demonstrated, containing intact monoclonal immunoglobulins (M-Igs) in 74% and FLCs only in 8% of cases. However, 18% contained a mixture of both cell populations. Progression from cells making intact M-Ig to cells restricted to FLC only production occurred in individual cases during the course of their disease. The presence of FLC only cells was associated with shortened survival.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17650446     DOI： 10.3324/haematol.11133

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  7 in total

1.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

2.  Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients.

Authors:  Graham Peter Mead; Mark Trehane Drayson
Journal:  Blood       Date:  2009-08-20       Impact factor: 22.113

3.  Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study.

Authors:  Nadia Wiazzane; Cyrus Chargari; Corine Plancher; Jerome Tamburini; Bernard Asselain; Alain Fourquet; Didier Bouscary; Youlia M Kirova
Journal:  World J Radiol       Date:  2013-06-28

4.  Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.

Authors:  Josip Batinić; Zinaida Perić; Dragana Šegulja; James Last; Sanja Prijić; Klara Dubravčić; Lidija Volarić; Dubravka Sertić; Ivo Radman; Sandra Bašić-Kinda; Danica Matišić; Drago Batinić; Boris Labar; Damir Nemet
Journal:  Croat Med J       Date:  2015-06       Impact factor: 1.351

Review 5.  Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma.

Authors:  Sara Ovejero; Jerome Moreaux
Journal:  Explor Target Antitumor Ther       Date:  2021-02-28

6.  Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma.

Authors:  Efstathios Koulieris; Panayiotis Panayiotidis; Stephen J Harding; Nikolitsa Kafasi; Dimitris Maltezas; Vassiliki Bartzis; Tatiana Tzenou; Maria Dimou; George Georgiou; Ladan Mirbahai; Arthur R Bradwell; Marie-Christine Kyrtsonis
Journal:  Exp Hematol Oncol       Date:  2012-04-23

7.  Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland.

Authors:  Maria Kraj; Barbara Kruk; Kelly Endean; Krzysztof Warzocha; Katarzyna Budziszewska; Monika Dąbrowska
Journal:  Case Rep Hematol       Date:  2015-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.